Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Emory University
University of Wisconsin, Madison
University of California, San Diego
Emory University
University of California, San Diego
VLP Therapeutics
Inhibrx Biosciences, Inc
Nanobiotix
M.D. Anderson Cancer Center
Sanford Health
National Cancer Institute (NCI)
Celldex Therapeutics